Press releaseGlobe Newswire
Optimi Health
OPTH · CANADIAN
$3.25−$0.03 (−0.91%)TodayMarket closed ·
Prev close $3.28
Latest news
- Press releaseGlobe Newswire
Optimi Health to Present at the ThinkEquity Conference
- Press releaseGlobe Newswire
Optimi Health Appoints Melanie Pump to Board of Directors
- Press releaseGlobe Newswire
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
- Press releaseGlobe Newswire
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
- NewsRishabh Mishra
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial
- Press releaseGlobe Newswire
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
- Press releaseGlobe Newswire
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
- Press releaseGlobe Newswire
Optimi Health Establishes Discretionary Equity Facility
- Press releasePRNewswire
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- News
Optimi Health Exports Third Shipment Of Its 5Mg Psilocybin Product To Australia Since September 2025
- Press releaseGlobe Newswire
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Press releasePRNewswire
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
- Press releasePRNewswire
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
- Press releasePRNewswire
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
- Press releaseGlobe Newswire
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
- Press releasePRNewswire
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
- Press releasePRNewswire
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.